Iressa and Hypercalcaemia - a phase IV clinical study of FDA data

Summary:

Hypercalcaemia is reported as a side effect among people who take Iressa (gefitinib), especially for people who are male, 60+ old, have been taking the drug for < 1 month also take Carboplatin, and have Lung cancer - non-small cell.

The phase IV clinical study analyzes which people have Hypercalcaemia when taking Iressa. It is created by eHealthMe based on reports of 10,081 people who have side effects when taking Iressa from the FDA, and is updated regularly.

What is Iressa?

Iressa has active ingredients of gefitinib. eHealthMe is studying from 10,102 Iressa users. Check the latest studies of Iressa.

What is Hypercalcaemia?

Hypercalcaemia (elevated calcium (ca+) level in the blood) is found to be associated with 1,059 drugs and 1,017 conditions by eHealthMe. Check the latest studies of Hypercalcaemia.

On Jul, 27, 2026

10,081 people reported to have side effects when taking Iressa.
Among them, 27 people (0.27%) have Hypercalcaemia.

Among these 27 people:

How long have people been on Iressa when they have Hypercalcaemia? *

What is the gender of people who have Hypercalcaemia when taking Iressa? *

female: 7.41 %
male: 92.59 %

What is the age of people who have Hypercalcaemia when taking Iressa? *

What are other drugs people take besides Iressa? *

What are other side effects people have besides Hypercalcaemia? *

Pneumonia: 9 people, 33.33%
Dehydration (dryness resulting from the removal of water): 8 people, 29.63%
Infection: 7 people, 25.93%
Malignant Neoplasm Progression (cancer tumour came back): 6 people, 22.22%
Acute Kidney Failure: 5 people, 18.52%
Acute Respiratory Failure: 5 people, 18.52%
Dyspnea (difficult or laboured breathing): 5 people, 18.52%
General Physical Health Deterioration (weak health status): 5 people, 18.52%
Lung Disorder (lung disease): 4 people, 14.81%
Oesophagitis (inflammation of oesophagus): 4 people, 14.81%

What are the existing conditions these people have? *

Lung Cancer - Non-Small Cell (lung cancer): 13 people, 48.15%
Small Cell Carcinoma (small cell cancer tumour): 3 people, 11.11%
Pain: 3 people, 11.11%
Oesophagitis (inflammation of oesophagus): 3 people, 11.11%
Lung Adenocarcinoma (a form of non-small cell lung cancer): 3 people, 11.11%
Squamous Cell Carcinoma (a cancer of a kind of epithelial cell): 2 people, 7.41%
Hypoaesthesia (reduced sense of touch or sensation): 2 people, 7.41%
High Blood Pressure: 2 people, 7.41%
High Blood Cholesterol: 2 people, 7.41%
Metastatic Renal Cell Carcinoma (spreadable kidney cell tumour): 1 person, 3.70%

* Approximation only. Some reports may have incomplete information.

Do you take Iressa and have Hypercalcaemia?

- Check whether Hypercalcaemia is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Iressa:

Iressa (10,102 reports)

Hypercalcaemia treatments and more:

Hypercalcaemia (18,731 reports)

Browse all side effects of Iressa:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Hypercalcaemia:

Hypercalcaemia (1,059 drugs)

Browse all the conditions that are associated with Hypercalcaemia:

Hypercalcaemia (1,017 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on gefitinib (the active ingredients of Iressa) and Iressa (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.